Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis

Ayalew Tefferi, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh Pardanani

Research output: Contribution to journalLetterpeer-review

10 Scopus citations
Original languageEnglish (US)
Pages (from-to)678-681
Number of pages4
JournalBritish journal of haematology
Volume183
Issue number4
DOIs
StatePublished - Nov 2018

Keywords

  • allogeneic
  • primary myelofibrosis
  • prognosis
  • survival
  • transplant

ASJC Scopus subject areas

  • Hematology

Cite this